RASAL1 inhibits HepG2 cell growth via HIF‑2α mediated gluconeogenesis

Meng,Fanhua; Zhang,Wei; Wang,Yufeng

doi:10.3892/ol.2017.7123

RASAL1 inhibits HepG2 cell growth via HIF‑2α mediated gluconeogenesis

Authors:
- Fanhua Meng
- Wei Zhang
- Yufeng Wang
View Affiliations

Affiliations: Department of Neurology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Electrocardiography, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Ultrasonography, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: October 3, 2017 https://doi.org/10.3892/ol.2017.7123
Pages: 7344-7352
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RAS protein activator like 1 (RASAL1) is a member of the RAS GTPase‑activating protein (GAP) family, and has been identified as a tumor suppressor in various types of cancer. In the present study, it was determined that decreased levels of RASAL1 were accompanied by a higher pathological stage and larger tumor size in human liver cancer. Therefore, it was hypothesized that RASAL1 may serve an inhibitory role in liver cancer. In the present study, the following was demonstrated: i) Exogenous expression of RASAL1 may inhibit the proliferation and invasion ability of HepG2 cells; ii) overexpression of RASAL1 may downregulate HIF‑2α transcription activity and HIF‑2α‑mediated gluconeogenesis through extracellular signal‑related kinase 1/2 activation; iii) RASAL1 may reduce the xenograft tumor size in nude mice by inhibiting the expression of hypoxia‑inducible factor (HIF)‑2α and gluconeogenesis enzymes. These data suggest that the RASAL1/HIF‑2α axis may serve an essential role in the growth of HepG2 cells, and that this signaling cascade may be a novel therapeutic target for the treatment of liver cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Rebollo A and Martı́nez-A C: Ras proteins: Recent advances and new functions. Blood. 94:2971–2980. 1999.PubMed/NCBI
3	Qiao F, Su X, Qiu X, Qian D, Peng X, Chen H, Zhao Z and Fan H: Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells. Oncol Rep. 28:1475–1481. 2012. View Article : Google Scholar : PubMed/NCBI
4	Liu D, Yang C, Bojdani E, Murugan AK and Xing M: Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst. 105:1617–1627. 2013. View Article : Google Scholar : PubMed/NCBI
5	Tao H, Huang C, Yang JJ, Ma TT, Bian EB, Zhang L, Lv XW, Jin Y and Li J: MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology. 290:327–333. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ko KS, Tomasi ML and Iglesiasas AL: MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 290: Rosis, and hepatocellular carcinoma in mice. Hepatology. 52:2096–2108. 2010. View Article : Google Scholar : PubMed/NCBI
7	Semenza GL: Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:4010–4015. 2000.PubMed/NCBI
9	Weidemann A and Johnson R: Biology of HIF-1alpha. Cell Death Differ. 15:621–627. 2008. View Article : Google Scholar : PubMed/NCBI
10	Löfstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L and Påhlman S: Hypoxia inducible factor-2alpha in cancer. Cell Cycle. 6:919–926. 2007. View Article : Google Scholar : PubMed/NCBI
11	Peng J, Zhang L, Drysdale L and Fong GH: The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci. 97:pp. 8386–8391. 2000, View Article : Google Scholar : PubMed/NCBI
12	Tian H, Hammer RE, Matsumoto AM, Russell DW and McKnight SL: The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12:3320–3324. 1998. View Article : Google Scholar : PubMed/NCBI
13	Wei K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, et al: A liver Hif-2 α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med. 19:1331–1337. 2013. View Article : Google Scholar : PubMed/NCBI
14	Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN, LaGory EL, Wei K, McGinnis LM, Yuan J, Kuo CJ and Giaccia AJ: Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med. 19:1325–1330. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ramakrishnan SK, Zhang H, Takahashi S, Centofanti B, Periyasamy S, Weisz K, Chen Z, Uhler MD, Rui L, Gonzalez FJ and Shah YM: HIF2α is an essential molecular brake for postprandial hepatic glucagon response independent of insulin signaling. Cell Metab. 23:505–516. 2016. View Article : Google Scholar : PubMed/NCBI
16	DeBerardinis RJ, Sayed N, Ditsworth D and Thompson CB: Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev. 18:54–61. 2008. View Article : Google Scholar : PubMed/NCBI
17	Sikes RS: The Animal Care and Use Committee of the American Society of Mammalogists: 2016 Guidelines of the American Society of Mammalogists for the use of wild mammals in research and education. J Mammalogy. 97:663–688. 2016. View Article : Google Scholar
18	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S and Muramatsu T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64:3365–3370. 2004. View Article : Google Scholar : PubMed/NCBI
21	McClain DA, Abuelgasim KA, Nouraie M, Salomon-Andonie J, Niu X, Miasnikova G, Polyakova LA, Sergueeva A, Okhotin DJ, Cherqaoui R, et al: Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: A role for HIF in glucose metabolism. J Mol Med (Berl). 91:59–67. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, et al: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology. 136:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
23	Qiao F, Su X, Qiu X, Qian D, Peng X, Chen H, Zhao Z and Fan H: Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells. Oncol Rep. 28:1475–1481. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J, et al: Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA. 104:pp. 12353–12358. 2007, View Article : Google Scholar : PubMed/NCBI
25	Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami R: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
26	Chen H, Yang XW, Zhang H, Yang Q, Wang Z, Liu Y, Lu FL, Zhou BY, Qiu-Xi CH and Lu SL: In vivo and in vitro expression of the RASAL1 gene in human gastric adenocarcinoma and its clinicopathological significance. Oncol Lett. 3:535–540. 2012.PubMed/NCBI
27	Jin W, Chen L, Cai X, Zhang Y, Zhang J, Ma D, Cai X, Fu T, Yu Z, Yu F and Chen G: Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 37:273–280. 2017. View Article : Google Scholar : PubMed/NCBI
28	Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:7106–7113. 2000.PubMed/NCBI
29	Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible factors HIF-1alpha and HIF-2 alpha in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62:2493–2497. 2002.PubMed/NCBI
30	Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, et al: Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell. 8:131–141. 2005. View Article : Google Scholar : PubMed/NCBI
31	Kondo K, Klco J, Nakamura E, Lechpammer M and Kaelin WG Jr: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:237–246. 2002. View Article : Google Scholar : PubMed/NCBI
32	Hur E, Chang KY, Lee E, Lee S-K and Park H: Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol. 59:1216–1224. 2001.PubMed/NCBI
33	Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q and Haase VH: Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 29:4527–4538. 2009. View Article : Google Scholar : PubMed/NCBI